A class action lawsuit has been filed against Aquestive Therapeutics and certain officers for alleged securities fraud. The complaint alleges that defendants made materially false statements regarding the timeline for FDA approval of Anaphylm and concealed significant human factors risks associated with the sublingual film product that could impact regulatory approval.

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Eos Energy Enterprises, Soleno Therapeutics, Nektar Therapeutics, and Driven Brands Holdings Inc. The lawsuits allege that these companies made false or misleading statements regarding their operations, financial reporting, and business prospects. Lead plaintiff deadlines range from May 5-8, 2026.

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to proposed mergers and acquisitions. The firm is examining whether McCormick & Company's merger with Unilever's Foods business, Odyssey Marine Exploration's merger with American Ocean Minerals Corporation, Soleno Therapeutics' sale to Neurocrine Biosciences, and Forian Inc.'s sale to a consortium led by its CEO are providing fair consideration to shareholders. The firm suggests insiders may receive substantial benefits unavailable to ordinary shareholders and seeks increased consideration and additional disclosures on behalf of investors.

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholder interests.

The Portnoy Law Firm has announced a class action lawsuit on behalf of Soleno Therapeutics investors who purchased securities between March 6, 2025 and November 4, 2025. The lawsuit alleges that Soleno concealed significant safety risks related to its lead drug DCCR, including excess fluid retention issues discovered in Phase 3 trials. The stock declined 27% on November 4, 2025 following disclosure of commercial disruption and a patient death, with investors having until May 5, 2026 to file a lead plaintiff motion.

Rosen Law Firm is soliciting investors with losses exceeding $100,000 in Super Micro Computer, Eos Energy Enterprises, and Soleno Therapeutics to join securities class action lawsuits. The Super Micro case alleges the company made false statements about its business while concealing that a significant portion of server sales violated U.S. export control laws and that material weaknesses existed in compliance controls. The lead plaintiff deadline is May 26, 2026.

Rosen Law Firm is encouraging investors with losses exceeding $100K in Eos Energy Enterprises, Soleno Therapeutics, and New Era Energy & Digital to join securities class action lawsuits. The lawsuits allege that defendants made false statements regarding production capabilities, operational performance, and business prospects. The lead plaintiff deadline is May 5, 2026.

Rosen Law Firm is encouraging investors with losses exceeding $100,000 to join securities class action lawsuits against Soleno Therapeutics, Eos Energy Enterprises, and New Era Energy & Digital. The primary focus is on Soleno, which faces allegations of concealing safety concerns related to its DCCR drug candidate for Prader-Willi syndrome, including fluid retention issues and materially lower commercial viability. The lead plaintiff deadline is May 5, 2026.

A class action lawsuit has been filed against Soleno Therapeutics for allegedly failing to disclose significant safety concerns about its drug DCCR, including fluid retention issues in clinical trials. The lawsuit was triggered by a critical report from Scorpion Capital in August 2025 and a patient death disclosure in September 2025, both causing substantial stock price declines. Investors who purchased SLNO stock between March 26, 2025 and November 4, 2025 can seek appointment as lead plaintiff by May 5, 2026.

Kahn Swick & Foti, LLC announced multiple securities class action lawsuits against Gemini Space Station, Inc., Soleno Therapeutics, Inc., and Navan, Inc. for alleged material misstatements and omissions in offering documents and public statements. Investors who purchased shares during specified class periods are eligible to participate, with application deadlines ranging from April 24 to May 18, 2026.

Kahn Swick & Foti, LLC announced multiple class action securities lawsuits against Enphase Energy, Soleno Therapeutics, and Navan Inc. for alleged securities fraud. Enphase is accused of overstating inventory management capabilities and financial prospects during April-October 2025. Investors have until specified deadlines to apply as lead plaintiffs.

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws and breaches of fiduciary duties. The investigations concern Soleno Therapeutics' sale to Neurocrine Biosciences, Forian's sale to a consortium led by its CEO, McCormick & Company's merger with Unilever's Foods business, and Cyclerion Therapeutics' merger with Korsana Biosciences. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.